The United States-Mexico-Canada Agreement (USMCA) provisions on the term of protection of test data for new pharmaceutical products has received considerable attention, and in some cases, some inaccurate reports on the agreement have conflated the term for test data protection… Continue Reading
On Tuesday, 25 September 2018, Knowledge Ecology International delivered the following opening statement at the 2018 WIPO General Assembly. Opening Statement, Knowledge Ecology International KEI would like WIPO to continue work on, and evaluate the progress of, the obligation that… Continue Reading
On Thursday, 20 September 2018, Knowledge Ecology International (KEI) delivered the following statement in Rome during discussions at the WHO Regional Committee for Europe on the WHO Roadmap on Access to Medicines and Vaccines. Oral statement of Knowledge Ecology International… Continue Reading
On August 20, 2018, KEI filed comments in response to the US Federal Trade Commission’s hearings and public comment process to address, “Competition and Consumer Protection in the 21st Century.” The goal of the process is to examine, “whether broad-based… Continue Reading
The following are comments by the KEI on the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs, in response to notice in the Federal Register, 83 FR 22692. Overall, the Blueprint is very weak, and won’t do much… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the NIH license of CD30 CAR T patents to Gilead. On April 11, 2019, the lawsuit was dismissed on the grounds that KEI lacked standing. KEI blogs January 5, 2018. 2018: Briefing note… Continue Reading
On Monday, 9 July 2018, Knowledge Ecology International (KEI) made the following statement on exceptions and limitations to patent rights. KEI made the following proposal: In terms of future work on this item on exceptions and limitations to patent rights,… Continue Reading
On June 25, 2018, plaintiff KEI filed a memorandum in opposition to a motion to dismiss filed by defendants NIH et al. The opposition cites the declaration of KEI Director James Love. The original KEI complaint is here: https://www.keionline.org/27669 The… Continue Reading
At the 71st World Health Assembly, KEI will deliver the following intervention regarding the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property: 11.6 Global strategy and plan of action on public health, innovation and intellectual… Continue Reading
On March 8, 2018, USTR and the interagency committee on the Special 301 held a hearing. KEI was one of the groups testifying. More on this process here: https://keionline.org/ustr/special301 I began our oral testimony discussing President Trump’s promise, during the… Continue Reading